100 related articles for article (PubMed ID: 21654834)
1. Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions.
Nardin A; Wong WC; Tow C; Molina TJ; Tissier F; Audebourg A; Garcette M; Caignard A; Avril MF; Abastado JP; Prévost-Blondel A
J Invest Dermatol; 2011 Sep; 131(9):1896-905. PubMed ID: 21654834
[TBL] [Abstract][Full Text] [Related]
2. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
3. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
4. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
Busch C; Geisler J; Lillehaug JR; Lønning PE
Eur J Cancer; 2010 Jul; 46(11):2127-33. PubMed ID: 20541396
[TBL] [Abstract][Full Text] [Related]
5. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth.
Prada F; Benedetti LG; Bravo AI; Alvarez MJ; Carbone C; Podhajcer OL
J Invest Dermatol; 2007 Nov; 127(11):2618-28. PubMed ID: 17625595
[TBL] [Abstract][Full Text] [Related]
6. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
7. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
Ma S; Egyházi S; Ueno T; Lindholm C; Kreklau EL; Stierner U; Ringborg U; Hansson J
Br J Cancer; 2003 Oct; 89(8):1517-23. PubMed ID: 14562026
[TBL] [Abstract][Full Text] [Related]
8. Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment.
Yoshimura T; Nagahara M; Kuo C; Turner RR; Soon-Shiong P; Hoon DS
Epigenetics; 2011 Aug; 6(8):1001-11. PubMed ID: 21725199
[TBL] [Abstract][Full Text] [Related]
9. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
Valero T; Steele S; Neumüller K; Bracher A; Niederleithner H; Pehamberger H; Petzelbauer P; Loewe R
J Invest Dermatol; 2010 Apr; 130(4):1087-94. PubMed ID: 19940857
[TBL] [Abstract][Full Text] [Related]
10. Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.
Failmezger H; Muralidhar S; Rullan A; de Andrea CE; Sahai E; Yuan Y
Cancer Res; 2020 Mar; 80(5):1199-1209. PubMed ID: 31874858
[TBL] [Abstract][Full Text] [Related]
11. Unraveling mysteries of the multifunctional protein SPARC.
Fukunaga-Kalabis M; Herlyn M
J Invest Dermatol; 2007 Nov; 127(11):2497-8. PubMed ID: 17934501
[TBL] [Abstract][Full Text] [Related]
12. Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.
Risberg K; Fodstad O; Andersson Y
J Immunother; 2010 Apr; 33(3):272-8. PubMed ID: 20445347
[TBL] [Abstract][Full Text] [Related]
13. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
14. SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated.
Haber CL; Gottifredi V; Llera AS; Salvatierra E; Prada F; Alonso L; Sage EH; Podhajcer OL
Int J Cancer; 2008 Apr; 122(7):1465-75. PubMed ID: 18059024
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Konjević G; Jović V; Radulović S; Jelić S; Dzodić R; Spuzić I
Neoplasma; 2001; 48(3):175-81. PubMed ID: 11583285
[TBL] [Abstract][Full Text] [Related]
16. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
18. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
20. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
Faião-Flores F; Quincoces Suarez JA; Fruet AC; Maria-Engler SS; Pardi PC; Maria DA
PLoS One; 2015; 10(3):e0118702. PubMed ID: 25742310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
